What is Finch Therapeutics Group Capex-to-Operating-Cash-Flow?
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.
Finch Therapeutics Group Capex-to-Operating-Cash-Flow Historical Data
The historical data trend for Finch Therapeutics Group's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Finch Therapeutics Group Capex-to-Operating-Cash-Flow Chart
Competitive Comparison of Finch Therapeutics Group's Capex-to-Operating-Cash-Flow
For the Biotechnology subindustry, Finch Therapeutics Group's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Finch Therapeutics Group's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Finch Therapeutics Group's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Finch Therapeutics Group's Capex-to-Operating-Cash-Flow falls into.
Finch Therapeutics Group Capex-to-Operating-Cash-Flow Calculation
Finch Therapeutics Group's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Finch Therapeutics Group (OTCPK:FNCH) Capex-to-Operating-Cash-Flow Explanation
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
Finch Therapeutics Group Capex-to-Operating-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Finch Therapeutics Group's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Finch Therapeutics Group (Finch Therapeutics Group) Business Description
Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The lead product candidate is CP101 which delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FNCH has been successfully added to your 